A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.

@article{Gerhartz1994ARP,
  title={A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.},
  author={Heinrich H. Gerhartz and R N Marcus and Alain Delmer and Heinz Zwierzina and Stefan Suciu and Mireille Dardenne and Gabriel Solbu and Theo de Witte and Andrew J. Jacobs and Giuseppe Visani},
  journal={Leukemia},
  year={1994},
  volume={8 1},
  pages={16-23}
}
In a randomized phase II study, patients with myelodysplastic syndromes (MDS) with 10-30% blasts in the bone marrow and hematopoietic failure were treated with low-dose Ara C (2 x 10 mg/m2 subcutaneously (s.c.) days 1-14) and rhGM-CSF (fully glycosylated, Sandoz/Schering-Plough, 2 x 150 micrograms protein/day s.c.) given either following Ara C (days 15-21) or simultaneously (days 8-14) for 1-5 cycles. 108 patients with a median age of 65 years, range 17-80 years and refractory anemia with an… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Phase I study of oral topotecan in hematological malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…